Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Myhep 400mg Tablets | 112-Count | SOFOSBUVIR / VELPATASVIR
Pharma

Myhep 400mg Tablets | 112-Count | SOFOSBUVIR / VELPATASVIR

$550

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse SOFOSBUVIR / VELPATASVIR — 400mg per tablet, 112-count pack. Pangenotypic HCV treatment — all genotypes 1–6. Single daily tablet for 12 weeks achieves over 97% cure rates in most patient populations. Key warning: Rifampin/carbamazepine dramatically reduce levels — avoid. Screen for HBV before starting (reactivation risk). Check HIV antiretroviral interactions.

SKU
VES-004977-MYHEP-400MG-112TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Myhep 400mg (1X28) (SOFOSBUVIR / VELPATASVIR)?

Pangenotypic HCV treatment — all genotypes 1–6. Single daily tablet for 12 weeks achieves over 97% cure rates in most patient populations.

How it Works

Sofosbuvir (NS5B polymerase inhibitor) blocks viral RNA synthesis; velpatasvir (NS5A inhibitor) blocks viral replication complex assembly. Pan-genotypic dual mechanism.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
SOFOSBUVIR / VELPATASVIR
Dose per Tablet
400MG
Pack Size
112 tablets
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Headache, fatigue, nausea — generally mild. One of the best-tolerated antiviral regimens available.

Safety Warnings

Rifampin/carbamazepine dramatically reduce levels — avoid. Screen for HBV before starting (reactivation risk). Check HIV antiretroviral interactions. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.